Bio-Techne Q4 revenue rises 1% to $321.2 million; GAAP EPS $0.35 vs. loss a year ago
Bio-Techne reported fourth-quarter fiscal 2026 revenue of $321.2 million, up 1% as reported and 3% organic, with GAAP EPS of $0.35 versus a loss of $0.11 a year earlier. Adjusted EPS was $0.52, down from $0.53, and full-year adjusted EPS rose to $1.93 from $1.92 on flat revenue of $1.2 billion. The company said it will no longer hold quarterly investor calls because of its pending acquisition by Merck KGaA, Darmstadt, Germany, at $73 per share in cash.
Key points
- Q4 fiscal 2026 net sales were $321.2 million, up 1% reported and 3% organic.
- Q4 GAAP EPS was $0.35 versus $(0.11) a year earlier; adjusted EPS was $0.52 versus $0.53.
- Full-year fiscal 2026 net sales were flat at $1.2 billion; full-year adjusted EPS was $1.93 versus $1.92.
- Board declared an $0.08 per share dividend, payable September 4, 2026, to holders of record on August 24, 2026.
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.